LON:TCF Theracryf (TCF) Share Price, News & Analysis GBX 0.22 0.00 (0.00%) As of 03/28/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Theracryf Stock (LON:TCF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theracryf alerts:Sign Up Key Stats Today's Range 0.23▼ 0.2350-Day Range 0.20▼ 1.2252-Week Range 0.20▼ 1.25Volume3.00 million shsAverage Volume3.88 million shsMarket Capitalization£1.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.Read More… Remove Ads Receive TCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theracryf and its competitors with MarketBeat's FREE daily newsletter. Email Address TCF Stock News HeadlinesTheracryf Plc (TCF.L)January 19, 2025 | ca.finance.yahoo.comTheracryf PLC Share Chat (TCF)January 13, 2025 | lse.co.ukSee More Headlines TCF Stock Analysis - Frequently Asked Questions How have TCF shares performed this year? Theracryf's stock was trading at GBX 0.54 at the beginning of the year. Since then, TCF shares have decreased by 58.2% and is now trading at GBX 0.23. View the best growth stocks for 2025 here. How were Theracryf's earnings last quarter? Theracryf Plc (LON:TCF) posted its quarterly earnings results on Thursday, November, 28th. The company reported ($29.00) earnings per share (EPS) for the quarter. Theracryf had a negative trailing twelve-month return on equity of 99.97% and a negative net margin of 792.17%. How do I buy shares of Theracryf? Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings11/28/2024Today3/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryBanking Current SymbolLON:TCF CIKN/A Webtheracryf.com Phone44-1625-315-090FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,447,566.69 Net Margins-792.17% Pretax MarginN/A Return on Equity-99.97% Return on Assets-48.26% Debt Debt-to-Equity RatioN/A Current Ratio4.20 Quick RatioN/A Sales & Book Value Annual Sales£687,674.98 Price / Sales1.56 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 0.85 per share Price / Book0.26Miscellaneous Outstanding Shares477,357,778Free FloatN/AMarket Cap£1.07 million OptionableN/A Beta1.42 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:TCF) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theracryf Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Theracryf With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.